Multiple Myeloma Diagnostic Criteria (IMWG)
ورودیهای بالینی بیمار
پارامترهای بالینی بیمار را در فرم روبرو وارد کنید و روی «محاسبه» کلیک نمایید تا نمره، طبقه خطر و اقدامات فوری نمایش داده شوند.
- Not Diagnostic0–0
- Multiple Myeloma1–1
The Multiple Myeloma Diagnostic Criteria (IMWG) calculates determining thromboembolic risk, heparin-induced thrombocytopenia probability, and bleeding diathesis. Key inputs include clonal plasma cells bone marrow. Scores guide initiating targeted anticoagulation therapy, platelet monitoring, or hematology specialist referral. This standardized assessment improves clinical decision safety and bedside patient management.
Clinical Guidelines & Evidence
Diagnoses multiple myeloma according to the International Myeloma Working Group (IMWG) criteria, including traditional CRAB criteria and newer SLiM biomarkers.
Clinical Indication
The Multiple Myeloma Diagnostic Criteria (IMWG) is indicated for bedside clinical practice to support Diagnoses multiple myeloma according to the International Myeloma Working Group (IMWG) criteria, including traditional CRAB criteria and newer SLiM biomarkers.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.
Target Population
Target population comprises Patients presenting with coagulopathy, thrombocytopenia, venous thromboembolism (DVT/PE), or hematologic neoplasms. Clinical application is indicated across Hematology-oncology services, bone marrow transplant units, anticoagulation clinics, and acute medical wards.
Limitations & Contraindications
Severe thrombocytopenia with concomitant microvascular thrombosis (TTP, HIT, DIC) represents a medical emergency requiring rapid intervention.
Clinical Pearls & Action Plan
Detailed history of heparin exposure, platelet count kinetics, and comprehensive coagulation profiles are vital in consumptive coagulopathies. Guideline pearl: Early treatment may prevent progression to symptomatic multiple myeloma.
Multiple Myeloma Diagnosis = (Clonal plasma cells ≥10% OR Biopsy-proven plasmacytoma) AND ≥1 myeloma defining event (CRAB criteria: Hypercalcemia, Renal insufficiency, Anemia, Bone lesions; OR SLiM biomarkers: ≥60% plasma cells, Light chain ratio ≥100, >1 MRI focal lesion)
Input Parameters
| Name | Type | Required | Description |
|---|---|---|---|
| clonal_plasma_cells_bone_marrow | string | Yes | Clonal bone marrow plasma cells ≥10% |
| biopsy_proven_plasmacytoma | string | Yes | Biopsy-proven bony or extramedullary plasmacytoma |
| hypercalcemia | string | Yes | Hypercalcemia: Serum calcium >1 mg/dL above normal or >11 mg/dL |
| renal_insufficiency | string | Yes | Renal insufficiency: Creatinine clearance <40 mL/min or serum creatinine >2 mg/dL |
| anemia | string | Yes | Anemia: Hemoglobin >2 g/dL below normal or <10 g/dL |
| bone_lesions | string | Yes | Bone lesions: ≥1 osteolytic lesion on imaging |
| plasma_cells_60_percent | string | Yes | Clonal bone marrow plasma cells ≥60% |
| light_chain_ratio | string | Yes | Involved:uninvolved serum free light chain ratio ≥100 |
| focal_mri_lesions | string | Yes | >1 focal lesion on MRI |
Score Interpretation & Guidance
| Range | Stage | Description |
|---|---|---|
| 0–0 | Not Diagnostic | Criteria not met for multiple myeloma |
| 1–1 | Multiple Myeloma | Criteria met for multiple myeloma |
Evidence-Based References (EBM)
- Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15(12):e538-48. doi: 10.1016/S1470-2045(14)70442-5.DOI: 10.1016/S1470-2045(14)70442-5
- Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17(8):e328-e346. doi: 10.1016/S1470-2045(16)30206-6.DOI: 10.1016/S1470-2045(16)30206-6
- Palumbo A, Avet-Loiseau H, Oliva S, Lokhorst HM, Goldschmidt H, Rosinol L, et al. Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group. J Clin Oncol. 2015;33(26):2863-9. doi: 10.1200/JCO.2015.61.2267.DOI: 10.1200/JCO.2015.61.2267